Leerink an­a­lyst ad­justs nusin­ersen peak to $2.5B; Dai­ichi Sankyo signs up to work with Dana-Far­ber team

Count Ge­of­frey Porges in the mix of an­a­lysts cheer­ing Io­n­is $IONS and Bio­gen $BI­IB for­ward on fresh ev­i­dence of the ef­fi­ca­cy of nusin­ersen for spinal mus­cu­lar at­ro­phy. In a note to­day the Leerink an­a­lyst said that af­ter in­ves­ti­ga­tors re­lease more da­ta over the week­end, he views an ap­proval for Type 1 SMA as a “near cer­tain­ty.” And there’s some ev­i­dence to sug­gest that the up­side could be sig­nif­i­cant­ly broad­ened with ap­provals for Type II and Type III SMA as well. That is en­cour­ag­ing enough for Porges to boost his peak 2025 sales es­ti­mate to $2.5 bil­lion, 20% to 30% ahead of con­sen­sus. Both com­pa­nies bad­ly need a win here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER